A cross-border Life Sciences team advised Vaccitech (Nasdaq: VACC) in its initial public offering in the United States of 6,500,000 American Depositary Shares (ADSs) representing 6,500,000 ordinary shares at an initial public offering price of $17.00 per ADS for gross proceeds of $110.5 million. The ADSs are trading on The Nasdaq Global Market. Vaccitech granted the underwriters a 30-day option to purchase up to an additional 975,000 ADSs at the initial public offering price, less underwriting discounts and commissions.
Vaccitech is a clinical-stage biopharmaceutical company engaged in the discovery and development of novel immunotherapeutics and vaccines for the treatment and prevention of infectious diseases and cancer. The company’s proprietary platform comprises proprietary modified simian adenoviral vectors, known as ChAdOx1 and ChAdOx2, as well as the well-validated Modified Vaccinia Ankara, or MVA, boost vector, both with demonstrable safety profiles and without the ability to replicate in humans.
The Goodwin team was led by Robert Puopolo, Andrew Harrow and Marishka DeToy and included Michael Grainger, Matthew Shelley, Amanda Rae Schwarzenbart, Robert Young.
For additional details on the offering, please read the pricing press release.